

## PATENT COOPERATION TREATY

## PCT

REC'D 07 FEB 2006


WIPO

PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 101256-1 WO	<b>FOR FURTHER ACTION</b>	See Form PCT/PEA/416
International application No. PCT/GB2004/004784	International filing date (day/month/year) 15.11.2004	Priority date (day/month/year) 17.11.2003
International Patent Classification (IPC) or national classification and IPC A61K31/506, C07D403/12, C07D409/14, C07D495/04, C07D487/04, C07D471/04, C07D401/14, C07D417/04, C07D403/14, A61P35/00		
Applicant ASTRAZENECA AB		
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input type="checkbox"/> sent to the applicant and to the International Bureau) a total of sheets, as follows:</p> <p><input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>		
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the opinion</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input checked="" type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input type="checkbox"/> Box No. VIII Certain observations on the international application</p>		
Date of submission of the demand  27.07.2005	Date of completion of this report  06.02.2006	
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  Grassi, D  Telephone No. +49 89 2399-8499	



BEST AVAILABLE COPY

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/GB2004/004784

**Box No. I Basis of the report**

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
  - ☐ publication of the international application (under Rule 12.4)
  - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements\*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):*

**Description, Pages**

1-129 as originally filed

**Claims, Numbers**

1-28 as originally filed

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
  - ☐ the claims, Nos.
  - ☐ the drawings, sheets/figs
  - ☐ the sequence listing (*specify*):
  - ☐ any table(s) related to sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
  - ☐ the claims, Nos.
  - ☐ the drawings, sheets/figs
  - ☐ the sequence listing (*specify*):
  - ☐ any table(s) related to sequence listing (*specify*):

\* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/GB2004/004784

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,  
☒ claims Nos. 18-20,28

because:

- ☒ the said international application, or the said claims Nos. (with respect to industrial applicability) relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos.
- ☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
- |                            |  |
|----------------------------|--|
| the written form           | <input type="checkbox"/> has not been furnished            |
|                            | <input type="checkbox"/> does not comply with the standard |
| the computer readable form | <input type="checkbox"/> has not been furnished            |
|                            | <input type="checkbox"/> does not comply with the standard |
- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.
- ☐ See separate sheet for further details

**BEST AVAILABLE COPY**

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/GB2004/004784

**Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	12,15,18,22,25
	No: Claims	1-11,13,14,16,17,19-21,23,24,26-28
Inventive step (IS)	Yes: Claims	
	No: Claims	1-28
Industrial applicability (IA)	Yes: Claims	1-17,21-27
	No: Claims	

2. Citations and explanations (Rule 70.7):

**see separate sheet**

**BEST AVAILABLE COPY**

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.

PCT/GB2004/004784

Reference is made to the following documents:

D1: WO 03/048133 (cited in the application)

D2: WO 01/60816

**Re Item III**

Claims 18-20 and 28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

**Re Item V**

- 1) The subject-matter of present claims 1-11 and 13, 14, 16, 17, 19-21, 23, 24 and 26-28 is not new (Article 33(2) PCT).

The document D1 relates to (IGF-1R) tyrosine kinase inhibitors for the treatment of proliferative diseases as cancer (cf. page 18, 58 and 59). Consequently, D1 belongs to the same technical field as the present application and solves a closely related technical problem.

Due to the proviso, the present claims are novel over the examples of D1 (cf. examples 44, 45, 92). However, the subject-matter of the present claim 1-11 essentially overlaps the group of compounds defined in claim 8 of D1.

The range of the overlap can not be regarded as novel, because there is no new technical teaching in the range of the overlap and, as shown by the various examples falling within the scope of the present claims, the skilled person would seriously contemplate applying the technical teaching of D1 in the range of the overlap. Therefore the whole range of the overlap is not novel.

Considering the activity, the intended use and the preparation of the compounds of D1 (cf. pages 15 and 18-22), the claims 13, 14, 16, 17, 19-21, 23, 24 and 26-28 are also not novel.

- 1.1) The subject-matter of the present claims is seen as novel selection from the teaching of D2 for the following reasons.

While there is an overlap between the subject of the present claims and the group of compounds defined by claim 1 of D2 (R2 is NHR5 and R5 is alkyl substituted with aryl), there are no examples in D2 showing the said feature. Therefore, the subject-matter of the present claims is regarded as novel selection from the disclosure of D2.

- 2) The subject-matter of claims 12, 15, 18, 22, 25 and the novel part of claims 1-11 and 13, 14, 16, 17, 19-21, 23, 24 and 26-28 does not involve an inventive step (Article 33(3) PCT).

D2 represents the closest prior art and relates to inhibitor of tyrosine kinases as IGF-1 and TRKA (cf. page 18, example 24 and tables 2, 3).

The subject-matter of claim 1 consists in the selection of a of a group of compounds from the group described in document D2 (cf. above). Such a selection can only be regarded as inventive, if the selection presents unexpected effects or properties in relation to the rest of the range (cf. examples 1, 5-9 or 33-35). However, no such effects or properties are indicated in the application. Hence, no inventive step is present in the subject-matter of the claims.